Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.

Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES.

Cancer Res. 2008 Jul 15;68(14):5628-38. doi: 10.1158/0008-5472.CAN-07-3170.


Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells.

Kim CJ, Nishi K, Isono T, Okuyama Y, Tambe Y, Okada Y, Inoue H.

Mol Carcinog. 2009 Oct;48(10):953-64. doi: 10.1002/mc.20547.


Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.

Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES.

J Biol Chem. 2003 Aug 8;278(32):30339-47. Epub 2003 May 12. Erratum in: J Biol Chem. 2004 Jul 16;279(29):30914.


Controversial relationship between the expression of the RB pathway components and RB protein phosphorylation in human breast cancer.

Montanaro L, Vici M, Donati G, Ceccarelli C, Santini D, Treré D, Derenzini M.

Histol Histopathol. 2007 Jul;22(7):769-75.


Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity.

Lamb R, Lehn S, Rogerson L, Clarke RB, Landberg G.

Cell Cycle. 2013 Aug 1;12(15):2384-94. doi: 10.4161/cc.25403. Epub 2013 Jun 26.


Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.

Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R.

Oncogene. 2002 Nov 21;21(53):8158-65.


Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene.

Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C, Zhang J, Parysek LM, Knudsen KE.

Cancer Res. 2010 May 15;70(10):3975-84. doi: 10.1158/0008-5472.CAN-09-3468. Epub 2010 May 11.


Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, McNally S, Diehl A, Demichele A.

Anticancer Res. 2010 Apr;30(4):1279-85.


Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line.

Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, Muise-Helmericks R, Li WW, Fan J, Banerjee D, Bertino JR.

J Natl Cancer Inst. 1996 Sep 18;88(18):1269-75.


Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.

Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA, Sutherland RL.

Cancer Res. 2002 Dec 1;62(23):6916-23.


Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.

Wilcken NR, Prall OW, Musgrove EA, Sutherland RL.

Clin Cancer Res. 1997 Jun;3(6):849-54.


Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.

Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, Comstock C, Hyslop T, Knudsen KE, Sette C.

Cancer Res. 2010 Jan 1;70(1):229-39. doi: 10.1158/0008-5472.CAN-09-2788. Epub 2009 Dec 22.


Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.

Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL, Knudsen ES.

Oncogene. 2009 Apr 16;28(15):1812-20. doi: 10.1038/onc.2009.13. Epub 2009 Mar 16.


PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ.

Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.


Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.

Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2190-5. Epub 2006 Feb 6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk